Literature DB >> 21860259

Anti-angiogenesis immunotherapy.

Jonathan D Schoenfeld1, Glenn Dranoff.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21860259      PMCID： PMC3225770          DOI： 10.4161/hv.7.9.16407

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


× No keyword cloud information.
  96 in total

1.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Authors:  Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

2.  Synergy between tumor immunotherapy and antiangiogenic therapy.

Authors:  Smita Nair; David Boczkowski; Benjamin Moeller; Mark Dewhirst; Johannes Vieweg; Eli Gilboa
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

3.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

4.  Immunization with synthetic VEGF peptides in ovarian cancer.

Authors:  Bing Wang; Pravin T P Kaumaya; David E Cohn
Journal:  Gynecol Oncol       Date:  2010-09-06       Impact factor: 5.482

5.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity.

Authors:  Yurai Okaji; Nelson Hirokazu Tsuno; Joji Kitayama; Shinsuke Saito; Tsuyoshi Takahashi; Kazushige Kawai; Kentaro Yazawa; Masahiro Asakage; Nobukazu Hori; Toshiaki Watanabe; Yoichi Shibata; Koki Takahashi; Hirokazu Nagawa
Journal:  Cancer Sci       Date:  2004-01       Impact factor: 6.716

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 8.  Immature myeloid cells and cancer-associated immune suppression.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2002-04-24       Impact factor: 6.968

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440
View more
  9 in total

1.  Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors:  Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

2.  Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.

Authors:  Madelon Q Wentink; Tilman M Hackeng; Sebastien P Tabruyn; Wouter C Puijk; Klaus Schwamborn; Daniele Altschuh; Rob H Meloen; Teun Schuurman; Arjan W Griffioen; Peter Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

3.  Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.

Authors:  Matthias Piesche; Vincent T Ho; Haesook Kim; Yukoh Nakazaki; Michael Nehil; Nasser K Yaghi; Dmitriy Kolodin; Jeremy Weiser; Peter Altevogt; Helena Kiefel; Edwin P Alyea; Joseph H Antin; Corey Cutler; John Koreth; Christine Canning; Jerome Ritz; Robert J Soiffer; Glenn Dranoff
Journal:  Clin Cancer Res       Date:  2014-12-23       Impact factor: 12.531

4.  Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions.

Authors:  Esther Grueso; Cristina Sánchez-Martínez; Tania Calvo-López; Fernando J de Miguel; Noelia Blanco-Menéndez; Marian Fernandez-Estevez; Maria Elizalde; Jorge Sanchez; Omar Kourani; Diana Martin; Aroa Tato; Milagros Guerra; Germán Andrés; José M Almendral
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

Review 5.  Intertwined regulation of angiogenesis and immunity by myeloid cells.

Authors:  Lee B Rivera; Gabriele Bergers
Journal:  Trends Immunol       Date:  2015-03-11       Impact factor: 16.687

6.  Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer.

Authors:  Julia Femel; Elisabeth J M Huijbers; Falk Saupe; Jessica Cedervall; Lei Zhang; Pernilla Roswall; Erik Larsson; Helena Olofsson; Kristian Pietras; Anna Dimberg; Lars Hellman; Anna-Karin Olsson
Journal:  Oncotarget       Date:  2014-12-15

7.  Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma.

Authors:  Jing Liang; Xiaolin Liu; Qi Xie; Guoling Chen; Xingyu Li; Yanrui Jia; Beibei Yin; Xun Qu; Yan Li
Journal:  Chin J Cancer Res       Date:  2016-08       Impact factor: 5.087

Review 8.  Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.

Authors:  Elizabeth Allen; Rindert Missiaen; Gabriele Bergers
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2017-04-10

9.  PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study.

Authors:  Qing Wei; Xing Yuan; Jingjing Li; Qi Xu; Jieer Ying
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.